Core Insights - STERIS plc is a leading provider of infection prevention products and services, with a market capitalization of $25.7 billion, offering a diverse range of medical equipment and consumables [1][2] Company Overview - STERIS is categorized as a large-cap stock, emphasizing its significant size and influence in the medical devices industry, particularly in infection prevention [2] - The company’s diverse portfolio serves as a comprehensive solution for healthcare providers, enhancing revenue and customer retention [2] Stock Performance - STERIS shares have experienced a decline of 4.2% from their 52-week high of $268.60, reached on November 25 [3] - Over the past three months, the stock has gained 3.6%, underperforming the S&P 500 Index, which saw a 5% increase [3] - In the longer term, STERIS shares rose 6% over six months, lagging behind the S&P 500's 13.9% gains, but have outperformed the index with a 19.3% increase over the past 52 weeks compared to the S&P 500's 13% [4] Recent Financial Results - On November 5, STERIS reported Q2 results, with revenue of $1.5 billion, exceeding analyst expectations of $1.4 billion [5] - The adjusted EPS of $2.47 also surpassed analyst estimates by 5.1% [5] - In contrast, Stryker Corporation, a competitor, has seen its stock decline by 8.4% over the past 52 weeks [5] Analyst Sentiment - Wall Street analysts maintain a bullish outlook on STERIS, with a consensus "Moderate Buy" rating from nine analysts [6] - The mean price target for STERIS is $288.86, indicating a potential upside of 12.3% from current price levels [6]